# Fluticasone Propionate ```text DRUG INFORMATION ADULT - ( 2.2 ) • Treatment of asthma in patients aged 12 years and older: 100 mcg twice daily up to a maximum recommended dosage of 1,000 mcg twice daily. Source: US FDA label for fluticasone propionate (FLOVENT DISKUS), section 'dosage and administration', retrieved 2026-08-29 - ( 2.2 ) • Treatment of asthma in patients aged 4 to 11 years: 50 mcg twice daily up to a maximum recommended dosage of 100 mcg twice daily. Source: US FDA label for fluticasone propionate (FLOVENT DISKUS), section 'dosage and administration', retrieved 2026-08-29 - The recommended starting dosage for patients aged 12 years and older who are not on an inhaled corticosteroid (ICS) is 100 mcg twice daily, approximately 12 hours apart. Source: US FDA label for fluticasone propionate (FLOVENT DISKUS), section 'dosage and administration', retrieved 2026-08-29 CHILD - The safety and effectiveness of FLOVENT DISKUS in children aged 4 years and older have been established [see Adverse Reactions (6.1), Clinical Pharmacology (12.3), Clinical Studies (14.2)] . The safety and effectiveness of FLOVENT DISKUS in children younger than 4 years have not been established. Effects on Growth Orally inhaled corticosteroids may cause a reduction in growth velocity when administered to pediatric patients. Source: US FDA label for fluticasone propionate (FLOVENT DISKUS), section 'pediatric use', retrieved 2026-08-29 - • For oral inhalation only. ( 2.1 ) • Starting dosage is based on prior asthma therapy and disease severity. ( 2.2 ) • Treatment of asthma in patients aged 12 years and older: 100 mcg twice daily up to a maximum recommended dosage of 1,000 mcg twice daily. ( 2.2 ) • Treatment of asthma in patients aged 4 to 11 years: 50 mcg twice daily up to a maximum recommended dosage of 100 mcg twice daily. Source: US FDA label for fluticasone propionate (FLOVENT DISKUS), section 'dosage and administration', retrieved 2026-08-29 - A 52-week placebo-controlled trial to assess the potential growth effects of fluticasone propionate inhalation powder (FLOVENT ROTADISK) at 50 and 100 mcg twice daily was conducted in the U.S. in 325 prepubescent children (244 males and 81 females) aged 4 to 11 years. Source: US FDA label for fluticasone propionate (FLOVENT DISKUS), section 'pediatric use', retrieved 2026-08-29 RENAL IMPAIRMENT - Therefore, patients with hepatic disease should be closely monitored. 8.7 Renal Impairment Formal pharmacokinetic studies using FLOVENT DISKUS have not been conducted in patients with renal impairment. Source: US FDA label for fluticasone propionate (FLOVENT DISKUS), section 'use in specific populations', retrieved 2026-08-29 HEPATIC IMPAIRMENT - Hepatic impairment: Monitor patients for signs of increased drug exposure. Source: US FDA label for fluticasone propionate (FLOVENT DISKUS), section 'use in specific populations', retrieved 2026-08-29 - No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be ruled out. 8.6 Hepatic Impairment Formal pharmacokinetic studies using FLOVENT DISKUS have not been conducted in patients with hepatic impairment. Source: US FDA label for fluticasone propionate (FLOVENT DISKUS), section 'use in specific populations', retrieved 2026-08-29 PREGNANCY - Risk Summary There are insufficient data on the use of FLOVENT DISKUS in pregnant women. Source: US FDA label for fluticasone propionate (FLOVENT DISKUS), section 'pregnancy', retrieved 2026-08-29 - There are clinical considerations with the use of FLOVENT DISKUS in pregnant women. Source: US FDA label for fluticasone propionate (FLOVENT DISKUS), section 'pregnancy', retrieved 2026-08-29 - (See Clinical Considerations.) In animals, teratogenicity characteristic of corticosteroids, decreased fetal body weight, and/or skeletal variations in rats, mice, and rabbits were observed with subcutaneously administered maternal toxic doses of fluticasone propionate less than the maximum recommended human daily inhaled dose (MRHDID) on a mcg/m 2 basis. Source: US FDA label for fluticasone propionate (FLOVENT DISKUS), section 'pregnancy', retrieved 2026-08-29 BREASTFEEDING - In a pre- and post-natal development study in pregnant rats dosed from late gestation through delivery and lactation (Gestation Day 17 to Postpartum Day 22), fluticasone propionate was not associated with decreases in pup body weight, and had no effects on developmental landmarks, learning, memory, reflexes, or fertility at doses up to 0.2 times the MRHDID (on a mcg/m 2 basis with maternal subcutaneous doses up to 50 mcg/kg/day). Source: US FDA label for fluticasone propionate (FLOVENT DISKUS), section 'use in specific populations', retrieved 2026-08-29 - Other corticosteroids have been detected in human milk. Source: US FDA label for fluticasone propionate (FLOVENT DISKUS), section 'use in specific populations', retrieved 2026-08-29 - However, fluticasone propionate concentrations in plasma after inhaled therapeutic doses are low and therefore concentrations in human breast milk are likely to be correspondingly low [see Clinical Pharmacology (12.3)] . Source: US FDA label for fluticasone propionate (FLOVENT DISKUS), section 'use in specific populations', retrieved 2026-08-29 ``` --- Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement. [Privacy policy](/privacy)